🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Daniel V.T. Catenacci

ORCID: 0000-0001-7517-8020
MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

4in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 4 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 13 papers. Top paper: “MAHOGANY: Margetuximab Combination in HER2+ Unresectable/metastatic Gastric/gastroesophageal Junction Adenocarcinoma”.

MAHOGANY: Margetuximab Combination in HER2+ Unresectable/metastatic Gastric/gastroesophageal Junction Adenocarcinoma

Future Oncology(2021)10.2217/fon-2020-1007
N/A
0.691DataRank · unranked
99 citations

Minori Rosales, Hyun Cheol Chung, Harry H Yoon, Lin Shen, Markus Moehler +2 more

Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.3_suppl.160
N/A
0.652DataRank · unranked
76 citations

Peter C. Enzinger, Yoon-Koo Kang, Kensei Yamaguchi, Shukui Qin, Keun-Wook Lee +11 more

FIGHT: A phase 3 randomized, double-blind, placebo controlled study evaluating (bemarituzumab) FPA144 and modified FOLFOX6 (mFOLFOX6) in patients with previously untreated advanced gastric and gastroesophageal cancer with a dose finding phase 1 lead-in.

Journal of Clinical Oncology(2018)10.1200/jco.2018.36.15_suppl.tps4135
N/A
0.241DataRank · unranked
4 citations

Peter C. Enzinger, Anteneh A. Tesfaye, Mohamedtaki Abdulaziz Tejani, Janine Powers, Charlie Zhang +6 more

Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): Secondary and final primary efficacy analyses.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.4561
N/A
0DataRank · unranked
4 citations

Bryan Peterson, Leah M. Chase, Samantha Lomnicki, Anthony V. Serritella, Natalie Reizine +12 more

Evaluation of spatiotemporal heterogeneity of PDL1 expression in gastroesophageal adenocarcinoma (GEA) at baseline diagnosis and after chemotherapy.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.4528
N/A
0DataRank · unranked
1 citations

Bryan Peterson, Anthony V. Serritella, Natalie Reizine, Yan Wang, Daniel V.T. Catenacci +1 more

Exploring New Approaches for Locally Advanced Gastroesophageal Adenocarcinomas: TNT, Irinotecan, and ctDNA

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2777
N/A
0DataRank · unranked
0 citations

Daniel V.T. Catenacci

The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer

Annals of Oncology(2022)10.1016/j.annonc.2022.09.150
N/A
0DataRank · unranked
143 citations

Francesco Facchinetti, Daniel DiToro, Islam Baiev, Umair Majeed, Sylvia A. Reyes +24 more

Safety and efficacy of combining genotype-guided irinotecan (Iri) with 5FU, leucovorin (LV), oxaliplatin (Ox), and docetaxel (Tax) (gFOLFOXIRITAX): The I-FLOAT phase 1 dose-escalation study for advanced upper GI cancers.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.4_suppl.316
N/A
0DataRank · unranked
0 citations

Aurelie Desgardin, Chih‐Yi Liao, Ardaman Shergill, Natalie Reizine, Stephanie Moya +11 more

Assessment of the impact of FcγRIIIA single-nucleotide polymorphisms on the efficacy of IgG1 monoclonal antibodies in patients with advanced gastroesophageal adenocarcinoma

ESMO Gastrointestinal Oncology(2023)10.1016/j.esmogo.2023.08.011
N/A
0DataRank · unranked
0 citations

Nicholas Grewal, Bruce E. Peterson, Kelly Arndt, Daniela del Gaudio, Pan Liu +6 more

Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-2085
N/A
0DataRank · unranked
188 citations

Bryan Peterson, Anthony V. Serritella, Joseph Thomas, Natalie Reizine, Stephanie Moya +4 more

KRAS gene amplification to define a distinct molecular subgroup of gastroesophageal adenocarcinoma.

Journal of Clinical Oncology(2016)10.1200/jco.2016.34.15_suppl.4065
N/A
0DataRank · unranked
0 citations

Lindsay Alpert, Peng Xu, Sravya Tumuluru, Rajani Kanteti, Les Henderson +7 more

Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease

Cancer Discovery(2020)10.1158/2159-8290.cd-20-1408
N/A
0DataRank · unranked
71 citations

Stephanie Moya, Samantha Lomnicki, Leah M. Chase, Bryan Peterson, Natalie Reizine +19 more

Evaluation of spatiotemporal heterogeneity of tumor mutational burden (TMB) in gastroesophageal adenocarcinoma (GEA) at baseline diagnosis and after chemotherapy.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.4546
N/A
0DataRank · unranked
7 citations

Bryan Peterson, Anthony V. Serritella, Natalie Reizine, Yan Wang, Daniel V.T. Catenacci +1 more